Strategic Ventures Special Bulletin: Nanocrine Achieves Major Milestone - October 2024

As published in the SV October 2024 Newsletter

Dr. Patrick Calhoun at the National Cancer Institute laboratory

On Wednesday, October 1, 2024,  Dr. Patrick Calhoun, President and Chief Science Officer of Nanocrine, Inc., visited the laboratories of the National Cancer Institute (NCI),  and tested for the first time Nanocrine’s revolutionary plasmonic chip using living cells.

The plasmonic chip performed as expected, detecting in real time a specific messenger molecule (a protein known as “MMP-9”) as it was being released from human adenocarcinoma lung epithelial cells. After several years spent developing the processes to manufacture this revolutionary plasmonic imaging chip, Nanocrine has now achieved a major corporate milestone.

Nanocrine’s plasmonic imaging technology, licensed exclusively from the U.S. Dept. of the Navy, is the first technology that allows medical scientists the ability to detect instantly the ”messenger molecules” produced by cells.  Currently, we cannot see, detect, or identify signaling molecules in the cellular environment. This inability greatly limits our understanding of cell-to-cell communication, which is foundational to maintaining life and understanding human disease.

Having reached this important milestone, the Nanocrine team will continue testing and validating its plasmonic chip technology, preparing for initial marketing and sales commencing early next year. The products will be offered as single-use, sterile consumables that use standard light microscopes and do not require any additional instrumentation. 

For further information or to set up a meeting with Dr. Patrick Calhoun, please contact Mitchell Hauser.